Reduced-dose telaprevir-based triple antiviral therapy for recurrent hepatitis C after living donor liver transplantation

Transplantation

Volumn 98, Issue 9, 2014, Pages 994-999

  Ikegami, Toru ^a   Yoshizumi, Tomoharu ^a   Kato, Masaki ^a   Yamamoto, Satomi ^b   Fukuhara, Takasuke ^a,b   Matsuura, Yoshiharu ^b   Nakamura, Shota ^b   Itoh, Shinji ^a   Shirabe, Ken ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Hepatitis C; Interferon; Liver transplantation; Ribavirin; Telaprevir

Indexed keywords

CYCLOSPORIN A; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B; PREDNISOLONE; RIBAVIRIN; STEROID; TELAPREVIR; VIRUS RNA; ANTIVIRUS AGENT; CYCLOSPORIN; OLIGOPEPTIDE;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE (PEOPLE); KIDNEY DYSFUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PLASMA CELL HEPATITIS; PRIORITY JOURNAL; RASH; RECURRENT VIRUS INFECTION; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS MUTATION; WILD TYPE; BLOOD; COHORT ANALYSIS; COMPLICATION; END STAGE LIVER DISEASE; ETHNOLOGY; GENETICS; HAPLOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH THROUGHPUT SEQUENCING; JAPAN; MUTATION; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; ANEMIA; ANTIVIRAL AGENTS; COHORT STUDIES; CYCLOSPORINE; END STAGE LIVER DISEASE; FEMALE; GLOMERULAR FILTRATION RATE; HAPLOTYPES; HEMOGLOBINS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JAPAN; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MUTATION; OLIGOPEPTIDES; RECURRENCE; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84925020573     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000166     Document Type: Article

References (28)

1. Brown RS. Hepatitis C and liver transplantation. Nature 2005; 436: 973.
2. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
3. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766.
4. Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78.
5. Garg V, van Heeswijk R, Lee JE, et al. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20.
6. Werner CR, Egetemeyr DP, Lauer UM, et al. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464.
7. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78.
8. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690.
9. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrent after liver transplantation. Liver International 2013; 33: 56.
10. Kawaoka T, Takahashi S, Tatsukawa Y, et al. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res 2014. January 2, 2014. [Epub ahead of print].
11. Verbinnen T, Van Marck H, Vandenbroucke I, et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol 2010; 84: 11124.
12. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767.
13. Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology 2011; 54: 781.
14. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483.
15. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011; 55: 192.
16. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577.
17. Kugelmas M, Osgood MJ, Trotter JF, et al. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl 2003; 9: 1159.
18. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142: 1132.
19. Karino Y, Ozeki I, Hige S, et al. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C. J Viral Hepat 2014; 21: 341.
20. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorYsparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1.
21. Hara T, Akuta N, Suzuki F, et al. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. J Med Virol 2013; 85: 1746.
22. Ogawa E, Furusyo N, Nakamuta M, et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 2013; 38: 1076.
23. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372.
24. Ikegami T, Shirabe K, Fukuhara T, et al. Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation. Hepatol Res 2013; 43: 621.
25. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982.
26. Ikegami T, Shirabe K, Yoshizumi T, et al. Primary graft dysfunction after living donor liver transplantation is characterized by delayed functional hyperbilirubinemia. Am J Transplant 2012; 12: 1886.
27. Ikegami T, Toshima T, Takeishi K, et al. Bloodless splenectomy during liver transplantation for terminal liver diseases with portal hypertension. J Am Coll Surg 2009; 208: e1.
28. Motomura T, Shirabe K, Furusyo N, et al. Effect of laparoscopic splenectomy in patients with hepatitis C and cirrhosis carrying IL28B minor genotype. BMC Gastroenterol 2012; 12: 158.